Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D011-08 in Advanced Solid Tumors
NCT05099536Phase 1Withdrawn
- Sponsor
- 3D Medicines Inc.
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Light/Condition-Responsive Prodrugs, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 3D011-08 in solid tumor (advanced stage), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 1 more, sponsored by 3D Medicines Inc. Primary endpoints: Maximum Tolerated Dose at 24 months, Objective Response Rate at 24 months and 1 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
3D011-08
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05099536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099536.